132 results about "Evodiamine" patented technology

The invention relates to the technical field of medicines. The content of DNA topoisomerase I (TopoI) in tumor cells is substantially higher the content of the TopoI in normal tissues, and an inhibitor of the TopoI is listed as one of six types of antitumor drugs which are primarily researched by an American NCI (National Cancer Institute). The invention aims to obtain evodiamine derivatives withstrong antitumor activities by modifying the structure of evodiamine. The evodiamine structure of the evodiamine compounds is represented by general formula (I) in the specification. The invention also provides an application of the evodiamine compounds and medicinal salts thereof in preparing topoisomerase inhibitors and antitumor drugs.

The invention relates to an adjuvant for improving the effectiveness of a dendritic cell vaccine, which is a traditional Chinese medicine monomer, namely evodiamine.

The present invention provides a drug for treating hyperuricemia and gout, ie., evodiamine dispersion tablets. The evodiamine dispersion tablets are the preparation prepared from the following raw materials and additives, by weight, 7-13 parts of evodiamine, 30-50 parts of a solid dispersion water-soluble carrier material, 70-90 parts of a filler, and 8-14 parts of a disintegrating agent. The present invention further provides a preparation method and uses of the dispersion tablets. The evodiamine dispersion tablets of the present invention have characteristics of short disintegration time and high dispersion uniformity. According to the present invention, the dissolution of the insoluble drug evodiamine in the solid preparation can be significantly improved, the absorption of the evodiamine in the human body is prompted, the bioavailability of the drug is increased, and new selections are provided for clinical medication for treatments of hyperuricemia and gout.

The invention belongs to the field of pharmaceutic preparations, and relates to a formula and a preparation method of an evodiamine nanoemulsion. The evodiamine nanoemulsion prepared by the invention can be used for improving the solubility of medicines and enhancing the bioavailability and the pharmacological activity.

The invention discloses application of evodiamine and rutaecarpine in preparation of a medicine for enhancing the activation of NLRP3 inflammasomes. The evodiamine and the rutaecarpine can generate active Caspase-1 by enhancing activiation of macrophage inflammasomes so as to release manure inflammatory mediators such as IL-1beta and promote pyroptosis of sensitized macrophages. The activity of the evodiamine and the rutaecarpine can be used for enhancing the inflammatory response intensity of a human body and treating related diseases of insufficient activation of inflammasome including pulmonary tuberculosis and oral tuberculosis caused by intracellular infection of mycobacterium tuberculosis, diseases caused by listeria monocytogenes, related diseases caused by other intracellular infection bacteria, related diseases caused by pathogenic fungal infection, furunculosis, dental-root periapical diseases, chronic gastritis, chronic enteritis, dysentery and diarrhea and the like.

The invention discloses a pharmaceutical composition for treating hyperlipidemia as well as a preparation method and applications. The pharmaceutical composition comprises the following ingredients in parts by weight: 1-10 parts of evodiamine, and 5-15 parts of berberine. The pharmaceutical composition is prepared by combining active ingredients of natural pharmaceutical raw materials or the extract of active ingredients of pharmaceutical raw materials, is simple in constituents, is affirmed for curative effect, is not required for being decocted for administration, is convenient to carry and take after being prepared into tablets, capsules, pills, granules and oral liquid. Compared with the traditional natural pharmaceutical formulation, the composition has the advantages of less impurity content, high purity, clear action mechanism and stable character, is capable of better controlling the product quality in industrialization, and the like.

The invention relates to a processing method and detection method for integrating processing and preparing of evodia rutaecarpa in producing areas. The method directly dries in the shade, dries in thesun or dries by baking the fresh medicinal material of the evodia rutaecarpa, the processing method combines the initial processing in the producing areas of the evodia rutaecarpa and the processingof decoction pieces, and the fresh evodia rutaecarpa is directly processed into the evodia rutaecarpa decoction pieces. On the basis of the existing research on the evodia rutaecarpa, a evodia rutaecarpa one-test multiple evaluation method is established, the content of dehydroevodiamine, limonin, evodiamine, rutaecarpine and rutaecarpine in the evodia rutaecarpa is taken as indexes, a fingerprintspectrum and pharmacodynamics experiments are combined to integrally and systematically research the integrated technology of processing and preparing the evodia rutaecarpa in the producing areas, comparison research on decoction pieces processed by a traditional method is carried out, a scientific basis is provided for the standardization of the integrated technology of processing and preparingthe evodia rutaecarpa in the producing areas and a quality detection method of the evodia rutaecarpa, and the quality of the decoction pieces of the evodia rutaecarpa medicinal material and the safetyand the effectiveness of clinical application are improved.

The invention provides application of an evodiamine derivative in preparation of a medicine for treating superficial fungal infection. The evodiamine derivative disclosed by the invention is prepared by taking a methyl anthranilate compound and tryptamine as initial raw materials through amine-ester exchange and a one-step ring closing reaction catalyzed by Lewis acid. The evodiamine derivative disclosed by the invention can show good antibacterial activity on three fungi, namely trichophyton rubrum, trichophyton mentagrophytes and candida albicans. Moreover, cell walls, cell membranes and organelles of fungal spores are destroyed to a certain extent, the hydrophobicity of fungal biomembranes can be influenced to a certain extent, phenomena of dark red erythema, skin hardening and generation of a large amount of scurf caused by errhysis spots of skin subjected to dermabrasion treatment can be obviously relieved, and phenomena of thickened epidermal layer of skin tissue, small-area epidermal layer necrosis, cuticle small-area parakeratosis and the like are avoided. The evodiamine derivative has low toxicity and low drug resistance and can be applied to preparation of drugs for treating the superficial fungal infection.

The invention belongs to the field of medicaments, and provides the application of evodiamine in preparation of medicaments for treating alzheimer disease. The evodiamine can improve main symptoms of alzheimer disease, namely loss of learning and memory capability. The delay of the progression of alzheimer disease is mainly realized by: 1, inhibiting excessive activation of microglia in brain tissues, and lowering over-expression of cytokines IL-1, IL-6 and TNF-alpha; and 2, lowering expression of cycloxygenase-2, and inhibiting an inflammatory reaction of the central nervous system. Researches of curative effect and molecular mechanism on the evodiamine treating alzheimer disease prove that the evodiamine has quite good treating effect and has huge potential of becoming a clinical treatment medicament.

The invention relates to an extract containing evodiamine (EVO) and rutaecarpin (RUT) and a preparation method thereof. The invention further relates to a medical application of the extract. The ratio of the EVO to the RUT in the extract containing EVO and RUT provided by the invention is (1-10):(1-5). Compared with a chemically-synthesized monomer, the extract in a specific ratio has the advantages: the absorption of EVO and RUT can be improved remarkably, and the bioavailability of EVO and RUT is increased; and the extract is purity-dependent. The extract disclosed by the invention can be used for alleviating pain.

The invention discloses a temperature / pH responsive double-drug-loaded composite nano particle and a preparation method and use thereof. The temperature / pH responsive double-drug-loaded composite nanoparticle is obtained by sequentially preparing BBR@MSNp (NIPAM-co-MA), an LB film and LEBM. The preparation method comprises the steps that berberine (BBR) is loaded onto a specific-temperature and pH double-response functional nano particle, and then the nano particle is creatively coated with evodiamine (EVO), and the temperature / pH responsive double-drug-loaded composite nano particle is prepared. In vitro and in vivo experiments show that a targeted drug delivery system can accurately locate to a tumor site and achieve effective drug release. The EVO and BBR are subjected to combined administration through a temperature / pH responsive double-drug-loaded nano drug delivery system for the treatment of cancer, especially, a synergistic effect on the treatment of liver cancer, cervical cancer and breast cancer is achieved, and the curative effect is remarkable.